"Efficacy and Safety of Retaspimycin Hydrochloride (IPI-504) in Combination with Trastuzumab in Patients (pts) with Pretreated, Locally Advanced or Metastatic HER2-positive Breast Cancer" by Reshma Mahtani

Article

Efficacy and Safety of Retaspimycin Hydrochloride (IPI-504) in Combination with Trastuzumab in Patients (pts) with Pretreated, Locally Advanced or Metastatic HER2-positive Breast Cancer

Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting (2011)

Reshma Mahtani, Baptist Health South Florida
S. Modi
C. Saura
C. A. Henderson
N. U. Lin
J. Goddard
E. Rodenas
J. O'Shaughnessy
J. Baselga

Link

Disciplines

Medicine and Health Sciences

Publication Date

2011

Citation Information

Reshma Mahtani, S. Modi, C. Saura, C. A. Henderson, et al.. "Efficacy and Safety of Retaspimycin Hydrochloride (IPI-504) in Combination with Trastuzumab in Patients (pts) with Pretreated, Locally Advanced or Metastatic HER2-positive Breast Cancer" Journal of Clinical Oncology / American Society of Clinical Oncology (ASCO) Annual Meeting Vol. 29 Iss. 15s (2011) p. 590 - 590
Available at: http://works.bepress.com/reshma-mahtani/10/